The fact that cost growth is driven largely by older products and not by new blockbuster therapies “is particularly important,” write the authors, “because in the current value-based landscape, increasing drug costs attributable to new products can sometimes be justified on the basis of improved outcomes. However, rising costs due to inflation do not reflect improved value for patients.”
The rising cost of drugs is exerting a significant strain on the US healthcare system, prompting a number of proposed policy solutions—including an international reference pricing system and mandatory price disclosure in direct-to-consumer advertising—from the current administration. Innovative drugs with high list prices, including many specialty drugs, have often been pointed to as the culprits for the increasing cost burden, but new research suggests that price hikes on older drugs are also playing a substantial role in increasing costs.
A study published this week in Health Affairs sought to address the question of how much rising drug costs are linked to inflation in the prices of existing products versus the market entry of new therapies.
The investigators obtained monthly wholesale acquisition costs for all National Drug Codes (NDCs) for all oral and injectable drugs for the years 2008 to 2016. For each year, the investigators categorized drugs as either new or existing products, and as brand-name, specialty, or generic drugs.
Between the study period, the number of NDCs in the sample grew from 11,201 to 24,825 among oral drugs and from 1708 to 3047 for injectable drugs, and the average weighted costs of products increased across the study period among all classes:
The study’s authors concluded that prices increased “considerably faster” than inflation across all drug classes, with the highest increases for oral specialty drugs. Rising costs of brand-name products were driven by inflation of prices in existing products, and rising costs among specialty products were driven by combined new product entry and existing price inflation. Finally, more expensive new generics, increasing average weighted costs.
The fact that growth is driven largely by older products and not by new blockbuster therapies “is particularly important,” write the authors, “because in the current value-based landscape, increasing drug costs attributable to new products can sometimes be justified on the basis of improved outcomes. However, rising costs due to inflation do not reflect improved value for patients.”
Reference
Hernandez I, Good CB, Cutler DM, Gellad WF, Parekh N, Shrank WH. The contribution of new product entry versus existing product inflation in the rising cost of drugs [published online January 7, 2019]. Health Aff (Millwood). doi: 10.1377/hlthaff.2018.05147.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.